AR080888A1 - Uso de un derivado de acido graso para producir una composicion oftalmica - Google Patents

Uso de un derivado de acido graso para producir una composicion oftalmica

Info

Publication number
AR080888A1
AR080888A1 ARP110101238A ARP110101238A AR080888A1 AR 080888 A1 AR080888 A1 AR 080888A1 AR P110101238 A ARP110101238 A AR P110101238A AR P110101238 A ARP110101238 A AR P110101238A AR 080888 A1 AR080888 A1 AR 080888A1
Authority
AR
Argentina
Prior art keywords
subject
program
temperature
patient
central area
Prior art date
Application number
ARP110101238A
Other languages
English (en)
Spanish (es)
Inventor
Yukihiko Mashima
Ryuji Ueno
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Publication of AR080888A1 publication Critical patent/AR080888A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
ARP110101238A 2010-04-12 2011-04-12 Uso de un derivado de acido graso para producir una composicion oftalmica AR080888A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32333810P 2010-04-12 2010-04-12
US32334210P 2010-04-12 2010-04-12
US32681110P 2010-04-22 2010-04-22
US36294510P 2010-07-09 2010-07-09
US40823710P 2010-10-29 2010-10-29

Publications (1)

Publication Number Publication Date
AR080888A1 true AR080888A1 (es) 2012-05-16

Family

ID=44798822

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101238A AR080888A1 (es) 2010-04-12 2011-04-12 Uso de un derivado de acido graso para producir una composicion oftalmica

Country Status (9)

Country Link
US (2) US20110275715A1 (enExample)
EP (2) EP2558104A4 (enExample)
JP (3) JP5686819B2 (enExample)
KR (2) KR20130050939A (enExample)
CN (2) CN102933217A (enExample)
AR (1) AR080888A1 (enExample)
CA (2) CA2795720A1 (enExample)
TW (2) TW201204366A (enExample)
WO (2) WO2011129457A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ622403A (en) * 2009-11-27 2015-09-25 R Tech Ueno Ltd Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method
JP2014510709A (ja) * 2011-04-12 2014-05-01 株式会社アールテック・ウエノ 眼科用水性組成物
US20150037422A1 (en) * 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
JP6898429B2 (ja) * 2016-08-24 2021-07-07 ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ,ベイジン 黄斑変性症を治療するためのエンタカポン関連化合物
SG11202110789VA (en) * 2019-04-03 2021-10-28 Regenxbio Inc Gene therapy for eye pathologies
CA3158767A1 (en) * 2019-10-30 2021-05-06 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
MX2022009677A (es) 2020-02-06 2022-09-09 Perfuse Therapeutics Inc Composiciones para el tratamiento de enfermedades oculares.
MX2023012723A (es) 2021-04-30 2024-02-08 Perfuse Therapeutics Inc Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares.
CA3224494A1 (en) 2021-07-09 2023-01-12 Koen Vandyck Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545036B2 (en) * 2000-01-18 2003-04-08 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2003020283A2 (en) * 2001-08-29 2003-03-13 Novartis Ag Method for treating diabetic retinopathy
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
JP5222462B2 (ja) * 2003-08-21 2013-06-26 スキャンポ・アーゲー 眼科用組成物
EP1848541A4 (en) * 2005-02-07 2013-01-16 Pharmalight Inc METHOD AND DEVICE FOR THE OPHTHALMIC ADMINISTRATION OF PHARMACEUTICAL ACTIVE SUBSTANCES
US20100087540A1 (en) * 2008-10-07 2010-04-08 R-Tech Ueno, Ltd. Pharmaceutical composition

Also Published As

Publication number Publication date
CN102946883A (zh) 2013-02-27
US20110275711A1 (en) 2011-11-10
EP2558104A4 (en) 2013-12-11
KR20130099812A (ko) 2013-09-06
EP2558104A1 (en) 2013-02-20
WO2011129461A1 (en) 2011-10-20
CN102933217A (zh) 2013-02-13
TW201204366A (en) 2012-02-01
EP2558103A4 (en) 2013-09-25
KR20130050939A (ko) 2013-05-16
JP2016026182A (ja) 2016-02-12
TW201141486A (en) 2011-12-01
CA2795720A1 (en) 2011-10-20
JP2013523601A (ja) 2013-06-17
JP5878128B2 (ja) 2016-03-08
EP2558103A1 (en) 2013-02-20
JP2013528563A (ja) 2013-07-11
US20110275715A1 (en) 2011-11-10
JP5686819B2 (ja) 2015-03-18
CA2795723A1 (en) 2011-10-20
WO2011129457A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
AR080888A1 (es) Uso de un derivado de acido graso para producir una composicion oftalmica
Benito et al. Objective optical assessment of tear-film quality dynamics in normal and mildly symptomatic dry eyes
Colak et al. Comparison of corneal topographic measurements and high order aberrations in keratoconus and normal eyes
Orucoglu et al. Analysis of age, refractive error and gender related changes of the cornea and the anterior segment of the eye with Scheimpflug imaging
Wolsley et al. Investigation of changes in the myopic retina using multifocal electroretinograms, optical coherence tomography and peripheral resolution acuity
Pinero et al. Ocular scattering
Low et al. The outcomes of primary pediatric keratoplasty in Singapore
BR112013021153A2 (pt) dispositivo e métodos de rastreamento ocular de fotorrefração
Dysli et al. Fluorescence lifetime imaging in retinal artery occlusion
Read Ocular and environmental factors associated with eye growth in childhood
Jiang et al. Human conjunctival microvasculature assessed with a retinal function imager (RFI)
Loreck et al. Morning myopic shift and glare in advanced Fuchs endothelial corneal dystrophy
Nguyen et al. Aberrometry repeatability and agreement with autorefraction
Hilmi et al. Measurement of contrast sensitivity using the M&S Smart System II compared with the standard Pelli–Robson chart in patients with primary pterygium
Chakraborty et al. Diurnal variations in ocular aberrations of human eyes
Marcos-Fernández et al. Impact of herpetic stromal immune keratitis in corneal biomechanics and innervation
Hussein et al. The long-term outcomes in children who are not compliant with spectacle treatment for accommodative esotropia
Qiao et al. Full-field strain mapping for characterization of structure-related variation in corneal biomechanical properties using digital image correlation (DIC) technology
Aldossari et al. Effect of accommodation on peripheral eye lengths of emmetropes and myopes
Arranz-Márquez et al. Disminución de la agudeza visual
Gillmann et al. Relationship between contact lens sensor output parameters and visual field progression in open-angle glaucoma: assessment of a practical tool to guide clinical risk-assessment
Ortiz et al. Quantification and monitoring of visual disturbances for patients with cataracts using Halo v1. 0 software.
Ramamirtham et al. Monochromatic ocular wave aberrations in young monkeys
Chen et al. Comparison of wavefront aberrations in rabbit and human eyes
van Bree et al. Straylight values after refractive surgery: screening for ocular fitness in demanding professions

Legal Events

Date Code Title Description
FB Suspension of granting procedure